Significance:
Tumor suppressor PTEN is the second most mutated gene in human cancer. This study suggests, for the first time, that (IFN)-α, by suppressing the expression of its target gene, it may increase the expression of PTEN. Thus, pharmacological formulations encompassing “(IFN)-α or its activators” may be used to used to treat human cancers that retain wild-type PTEN.
Undisclosed information: How (IFN)-α increases the expression of PTEN.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Immuno therapy for Cancer: (IFN)-α increases the expression of tumor suppressor PTEN via down regulation of its target gene, 21/June/2015, 9.51 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
* Research cooperation